Related Experiment Videos
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and
R L Ho1, D Maccubbin, G Zaleskis
1Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY 14263.
Abstract:
This laboratory has extensively studied Adriamycin (doxorubicin)-induced immunomodulation. Despite demonstration of favorable effects, little therapeutic advantage was seen, and it was decided to test Adriamycin in combination with interleukin 2 (IL2). Considerable toxicity was seen with either high-dose IL2 or high-dose Adriamycin alone, using the syngeneic C57B1/6-EL4 T cell lymphoma model. When the doses of either agent were reduced to decrease toxicity, little therapeutic effect was seen. In contrast, an effective protocol without apparent toxicity was developed by combining a moderate dose of Adriamycin (4 mg/kg, IV, Days 1 and 8 or only Day 8) with prolonged administration of a moderate dose of IL2 (2 micrograms, b.i.d., i.p., Days 9 to 40). This protocol resulted in up to 80% long-term survivors among mice inoculated on Day 0 with EL4 lymphoma (5 x 10(4) cells). It should be noted that under these conditions, neither agent, when administered singly, induced long term survivors, and that following the inoculation of only 10-100 EL4 tumor cells all animals died in the absence of treatment. The survivors developed protective immunity as demonstrated by their ability to resist reimplantation with EL4 tumor. Furthermore, this resistance to tumor reimplantation could be transferred into naive hosts with spleen cells from tumor-bearing mice receiving the combination protocol; exposure of mice to sublethal whole body irradiation prior to tumor implantation completely abrogated the efficacy of this combination treatment. Finally, it was shown that this combination protocol was equally effective against an Adriamycin-resistant subline of EL4 that expresses the multidrug resistance phenotype.
Insights
Combining Adriamycin (doxorubicin) with interleukin 2 (IL2) effectively treats T cell lymphoma in mice. This novel protocol shows reduced toxicity and induces long-term survivors with protective immunity.
Area of Science:
- Immunology
- Medical Oncology
- Pharmacology
Background:
- Adriamycin (doxorubicin) has shown immunomodulatory effects but limited therapeutic advantage alone.
- High doses of Adriamycin or interleukin 2 (IL2) alone cause significant toxicity in the C57B1/6-EL4 T cell lymphoma model.
- Reduced doses of either agent individually yield minimal therapeutic benefits.
Purpose of the Study:
- To evaluate the efficacy and toxicity of a combination therapy using Adriamycin and IL2 for T cell lymphoma.
- To develop an optimized protocol for treating EL4 lymphoma with reduced adverse effects.
Main Methods:
- Mice with EL4 T cell lymphoma were treated with varying doses and schedules of Adriamycin and IL2.
- A combination protocol involved moderate doses of Adriamycin (4 mg/kg) and prolonged IL2 administration (2 µg, b.i.d.).
- Therapeutic efficacy was assessed by long-term survival rates, tumor resistance, and transfer of immunity via spleen cells.
Main Results:
- The combination protocol achieved up to 80% long-term survivors without apparent toxicity.
- Neither Adriamycin nor IL2 alone, at tested doses, induced long-term survival.
- Survivors developed protective immunity against EL4 tumor reimplantation, transferable via spleen cells.
- The combination therapy was effective against an Adriamycin-resistant EL4 subline expressing multidrug resistance.
Conclusions:
- A combination of moderate-dose Adriamycin and prolonged IL2 administration is a highly effective and non-toxic treatment for EL4 T cell lymphoma.
- This protocol induces durable anti-tumor immunity, offering a promising therapeutic strategy.
- The combination therapy overcomes multidrug resistance, suggesting broader applicability.